TY - JOUR
T1 - Dos métodos de anticoagulación en técnicas continuas de depuración extrarrenal
AU - Sorrosal, S.A.
AU - Marín, L.M.R.
AU - Torres, F.
AU - Jiménez, V.V.
AU - de Briñas, E.P.L.
N1 - Cited By :1
Export Date: 17 February 2022
Correspondence Address: Sorrosal, S.A.; Hospital Clínic de Barcelona, C/ Villarroel nº 170. Esc 10. 5ªPl, Spain; email: sarago@clinic.ub.es
Funding details: Division of Arctic Sciences, TIH13,24-25
Funding text 1: Aunque con una muestra de estudio pequeña, comparte resultados con otros estudios más extensos. Éstos han comparado la eficacia de la ARC y ASHS con diferen-tes métodos. Usando terapias de convección, hemofil-tración, convección y difusión, HDFVVC; con reposición de líquidos post-filtro o pre-filtro y con ASHS, o incluso de forma regional (administración de HS junto a protamina-ARH), de amplio uso en Australia y Nueva Ze-landa13-14, 24-25. Los estudios muestran mejor eficacia de la ARC, para mantener la permeabilidad del circuito extracorpóreo, evitar su coagulación y la aparición de TIH13,24-25.
References: Hoste, E.A., Clermont, G., Kersten, A., Venkataraman, R., Angus, D.C., De Bacquer, D., RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: A cohort analysis (2006) Crit Care, 10, p. 73; Richardson, A., Whatmore, J., Nursing essential principles: Continuous renal replacement therapy (2015) Nurs Crit Care, 20 (1), pp. 8-15; Romero, M., De La Cueva, L., Delgado, P., Actualización en técnicas continuas de reemplazo renal (2013) Enferm Int, 24 (3), pp. 113-119; Navas, A., Ferrer, R., Martínez, M., Martínez, M.L., De Haro, C., Artigas, A., Terapia de reemplazo renal en paciente crítico: Cambios evolutivos del tratamiento en los últimos años (2012) Med Int, 36 (8), pp. 540-547; Tomasa, T.M., Sabater, J., Poch, E., Fort, J., Lloret, M.J., Roca, J., Manejo actual de las terapias continuas de remplazo renal: Estudio epidemiológico multicéntrico (2017) Med Int, 41 (4), pp. 216-226; Rabindranth, K., Adams, J., Macleod, A.M., Muirhead, N., Intermittent versus continuous renal replacement therapy for acute renal failure in adults (2007) Cochrane Database of Syst Rev, (3); Bagshaw, S.M., Berthiaume, L.R., Delaney, A., Bellomo, R., Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury (2008) A Meta-Analysis. Crit Care Med., 36 (2), pp. 610-617; Ghahramani, N., Shadrou, S., Hollenbeak, C., A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure (2008) Nephrol, 13 (7), pp. 570-578; Kramer, P., Wigger, W., Rielger, J., Matthaei, D., Scheler, F., Arteriovenous haemofiltration: A new and simple method for trestment of over-hydrated patients resistant to diuretics (1977) Klin Wochenschr, 55 (22), pp. 1121-1122; Olert, A., Hernández, A.I., Miralles, F.J., Cortés, J., Domínguez, M.A., Caro, M.E., Experiencia con las técnicas continuas de reemplazo renal en cuidados intensivos (2008) Rev Soc Esp Enferm Nefrol, 11 (4), pp. 259-264; Molano, E., Guirao, A., Esteban, M.E., Sanz, P., García, E., Sánchez-Izquierdo, J.A., Detección de riesgos para la seguridad del paciente en la implementación de técnicas continuas de depuración extracorpórea (2011) Enferm Int, 22 (1), pp. 39-45; Syed, S., Reilly, R.F., Heparin-induced thrombocytopenia: A renal perspective (2009) Nat Rev Nephrol, 5, pp. 501-511; Gattas, D.J., Rajbhandari, D., Buhr, H., Bellomo, R., A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically III adults (2015) Crit Care Med, 48 (8), pp. 1622-1629; Gutiérrez-Bernays, D., Ostwald, M., Anstey, C., Campbell, V., Transition from heparin to citrate anticoagulation for continuous renal replacement therapy: Safety, efficiency, and cost (2016) Ther Apher Dial, 20 (1), pp. 53-59; Morita, Y., Johnson, R.W., Dorn, R.E., Hall, D.S., Regional anticoagulation during hemodialysis using citrate (1961) Am J Med, 242 (1), pp. 32-43; Von Brecht, J.H., Flanigan, M.J., Freeman, R.M., Lim, V.S., Regional anticoagulation: Hemodialysis with hipertonic trisodium citrate (1986) Am J Kidney Dis, 8 (3), pp. 196-201; Flanigan, M.J., Von Brecht, J.H., Freeman, R.M., Lim, V.S., Reducing the hemorrhagic complications of hemodialysis: A controlled comparison of low-dose heparin and citrate anticoagulation (1987) Am J Kidney Dis, 9 (2), pp. 147-153; Bellomo, R., Teede, H., Boyce, N., Anticoagulant regimens in acute continuous hemodiafiltration: A comparative study (1993) Int Med Care, 19 (6), pp. 329-332; Calatzis, A., Toepfer, M., Schramm, W., Spannagl, M., Schiffl, H., Citrate anticoagulation for extracorporeal circuits: Effects on whole blood coagulation activation and clot formation (2001) Nephrol, 89, pp. 233-236; James, M.F., Roche, A.M., Dose-response relationship between plasma ionized calcium concentration and thrombelastography (2004) J Cardiothorac Vasc Anesth, 18 (5), pp. 581-586; Carneiro, P., Santiago, M.J., López, J., Castillo, A., López-Herce, J., Anticoagulación regional con citrato en las técnicas de depuración extrarrenal continuas (2012) An Pediatr, 76 (1), pp. 49-52; Morgera, S., Scholle, C., Voss, G., Haase, M., Vargas-Hein, O., Krausch, D., Metabolic complications during regional citrate anticoagulation in continuous venovenuos hemodiafiltration (2004) Nephrol Clin Pract, 97 (4), pp. 131-136; Fernández, J., Oliveros, C.P., González, L.S., Gastelbondo, R., Mulett, H., Godoy, J., Guía de manejo anticoagulación con citrato de sodio para terapia de reemplazo renal en niños (2012) Acta Colom Cuid Int, 12 (3), pp. 179-184; Bai, M., Zhou, M., He, L., Ma, F., Li, Y., Yu, Y., Citrate versus heparin anticoagulation for continuous renal replacement therapy: An updated meta analysis of RCTs (2015) Int Med Care, 41 (12), pp. 2098-2110; Liu, C., Mao, Z., Kang, H., Hu, J., Zhou, F., Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: A meta-analysis with trial sequential analysis of randomized controlled trials (2016) Crit Care, 20 (1), pp. 1-13; Bellomo, R., Cass, A., Cole, L., Finfer, S., Gallagher, M., Intensity of continuous renal-replacement therapy in critically ill patients (2009) N Engl J Med, 361 (17), pp. 1627-1638. , The Renal Replacement Therapy Study Investigators; Park, J.S., Kim, G.H., Kang, C.M., Lee, C.H., Regional anticoagulation with citrate is superior to systemic anticoagulation with heparin in critically patients undergoing continuous venovenous hemodiafiltration (2011) Korean J Intern Med, 26 (1), pp. 68-75; De Vico, P., Messino, V., Tartaglione, A., Beccaris, C., Buonomo, C., Talarico, D., Safety and efficacy of citrate anticoagulation continuous renal replacement therapies in post-cardiac surgery patients with liver dysfunction (2015) Ther Apher Dial, 19 (3), pp. 272-278; Schultheiss, C., Saugel, B., Phillip, V., Thies, P., Noe, S., Mayr, U., Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: A prospective observational study (2012) Crit Care, 16, p. 162; KDIGO: Clinical practice guideline for the evaluation and management of acute kidney injury (2012) Kidney Int Suppl, 2 (3); Hafner, S., Stahl, W., Fels, T., Träger, K., Georgieff, M., Wepler, M., Implementation of continuous renal replacement therapy with regional citrate anticoagulation on a surgical and trauma intensive care unit: Impact on clinical and economic aspects-an observational study (2015) J Int Care, (3), pp. 35-43
PY - 2018
Y1 - 2018
N2 - Introduction: Continuous extra-renal depuration techniques are the therapy of choice in critically ill patients. But, they are not exempt from complications such as the coagulation of the extracorporeal circuit. The drug traditionally used for anticoagulation is sodium heparin. Although other methods of anticoagulation, such as citrate, are also used. Objective: To evaluate the efficacy and safety of two anticoagulation methods in patients treated with continuous therapies, in intensive care units of the Hospital Clinic of Barcelona. Material and Method: A retrospective observational study with 54 subjects was carried out. The criteria of acute renal insufficiency, described in the protocol “Guide for renal replacement therapy in acute renal failure at the Hospital Clínic” were applied. Patients were treated by hemodiafiltration, combining convection and diffusion therapies; with filtration fraction < 25%, and effluent dose of 30ml/kg/h. Twenty-seven subjects performed hemodiafiltration, pre-filter replacement and anticoagulation with sodium heparin. The rest, hemodiafiltration, post-filter replacement and anticoagulation with citrate. Episodes of bleeding and duration in hours of the extracorporeal circuits were evaluated during 72 hours of therapy. Results: Citrate demonstrated a greater survival of filters (95% CI, MD 65, 44.00-72.00 vs. MD 36.00, 15.00-22.00, p=0.02). Patients treated with heparin had more episodes of bleeding, without statistically significant differences (95% CI, n=6 vs. n=9, p=0.537). There was an episode of hypocalcemia in the citrate group, corrected according to protocol. In the heparin group, there were no cases of heparin-induced thrombocytopenia. Conclusions: The present study demonstrates greater efficacy in the survival of filters in the citrate group.
AB - Introduction: Continuous extra-renal depuration techniques are the therapy of choice in critically ill patients. But, they are not exempt from complications such as the coagulation of the extracorporeal circuit. The drug traditionally used for anticoagulation is sodium heparin. Although other methods of anticoagulation, such as citrate, are also used. Objective: To evaluate the efficacy and safety of two anticoagulation methods in patients treated with continuous therapies, in intensive care units of the Hospital Clinic of Barcelona. Material and Method: A retrospective observational study with 54 subjects was carried out. The criteria of acute renal insufficiency, described in the protocol “Guide for renal replacement therapy in acute renal failure at the Hospital Clínic” were applied. Patients were treated by hemodiafiltration, combining convection and diffusion therapies; with filtration fraction < 25%, and effluent dose of 30ml/kg/h. Twenty-seven subjects performed hemodiafiltration, pre-filter replacement and anticoagulation with sodium heparin. The rest, hemodiafiltration, post-filter replacement and anticoagulation with citrate. Episodes of bleeding and duration in hours of the extracorporeal circuits were evaluated during 72 hours of therapy. Results: Citrate demonstrated a greater survival of filters (95% CI, MD 65, 44.00-72.00 vs. MD 36.00, 15.00-22.00, p=0.02). Patients treated with heparin had more episodes of bleeding, without statistically significant differences (95% CI, n=6 vs. n=9, p=0.537). There was an episode of hypocalcemia in the citrate group, corrected according to protocol. In the heparin group, there were no cases of heparin-induced thrombocytopenia. Conclusions: The present study demonstrates greater efficacy in the survival of filters in the citrate group.
KW - Acute renal failure
KW - Citrate
KW - Continuous therapy
KW - Extra-renal depuration
KW - Heparin
KW - Regional anticoagulation
UR - http://www.scopus.com/inward/record.url?scp=85047566195&partnerID=8YFLogxK
U2 - 10.4321/S2254-28842018000100002
DO - 10.4321/S2254-28842018000100002
M3 - Artículo
AN - SCOPUS:85047566195
VL - 21
SP - 9
EP - 17
IS - 1
ER -